Cyclopharm Ltd (AU:CYC) — Market Cap & Net Worth
Market Cap & Net Worth: Cyclopharm Ltd (CYC)
Cyclopharm Ltd (AU:CYC) has a market capitalization of $61.87 Million (AU$87.44 Million) as of May 4, 2026. Listed on the AU stock exchange, this Australia-based company holds position #21055 globally and #742 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cyclopharm Ltd's stock price AU$0.73 by its total outstanding shares 120610534 (120.61 Million). Analyse CYC cash flow metrics to see how efficiently the company converts income to cash.
Cyclopharm Ltd Market Cap History: 2015 to 2026
Cyclopharm Ltd's market capitalization history from 2015 to 2026. Data shows growth from $40.97 Million to $61.87 Million (4.99% CAGR).
Cyclopharm Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cyclopharm Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.91x
Cyclopharm Ltd's market cap is 4.91 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $40.97 Million | $12.58 Million | $4.79 Million | 3.26x | 8.55x |
| 2016 | $72.69 Million | $14.39 Million | $891.37K | 5.05x | 81.55x |
| 2017 | $77.55 Million | $13.19 Million | -$1.52 Million | 5.88x | N/A |
| 2018 | $91.09 Million | $13.40 Million | -$35.46K | 6.80x | N/A |
| 2019 | $98.08 Million | $14.08 Million | -$2.91 Million | 6.97x | N/A |
| 2020 | $209.78 Million | $14.68 Million | -$6.04 Million | 14.29x | N/A |
| 2021 | $138.30 Million | $17.70 Million | -$5.04 Million | 7.81x | N/A |
| 2022 | $99.31 Million | $23.22 Million | -$6.61 Million | 4.28x | N/A |
| 2023 | $164.28 Million | $26.34 Million | -$4.70 Million | 6.24x | N/A |
| 2024 | $135.26 Million | $27.57 Million | -$13.20 Million | 4.91x | N/A |
Competitor Companies of CYC by Market Capitalization
Companies near Cyclopharm Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Cyclopharm Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #246 globally with a market cap of $99.71 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #441 globally with a market cap of $59.14 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #570 globally with a market cap of $45.94 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1111 globally with a market cap of $22.95 Billion USD ( AU$32.44 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #246 | McKesson Corporation | NYSE:MCK | $99.71 Billion | $814.02 |
| #441 | Cencora Inc. | NYSE:COR | $59.14 Billion | $304.00 |
| #570 | Cardinal Health Inc | NYSE:CAH | $45.94 Billion | $195.24 |
| #1111 | Sigma Healthcare Ltd | AU:SIG | $22.95 Billion | AU$2.81 |
Cyclopharm Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Cyclopharm Ltd's market cap moved from $40.97 Million to $ 61.87 Million, with a yearly change of 4.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$61.87 Million | -26.02% |
| 2025 | AU$83.63 Million | -38.17% |
| 2024 | AU$135.26 Million | -17.66% |
| 2023 | AU$164.28 Million | +65.42% |
| 2022 | AU$99.31 Million | -28.19% |
| 2021 | AU$138.30 Million | -34.07% |
| 2020 | AU$209.78 Million | +113.89% |
| 2019 | AU$98.08 Million | +7.67% |
| 2018 | AU$91.09 Million | +17.46% |
| 2017 | AU$77.55 Million | +6.68% |
| 2016 | AU$72.69 Million | +77.42% |
| 2015 | AU$40.97 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Cyclopharm Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $61.87 Million USD |
| MoneyControl | $61.87 Million USD |
| MarketWatch | $61.87 Million USD |
| marketcap.company | $61.87 Million USD |
| Reuters | $61.87 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribu… Read more